Clinical Perspectives: Utilizing CAR-T Therapy in R/R MM
Panelists discuss how emerging data on chimeric antigen receptor T-cell therapies ciltacabtagene autoleucel and idecabtagene vicleucel for earlier treatment lines in relapsed/refractory multiple myeloma influence institutional decision-making factors for their implementation.
Video content above is prompted by the following:
- Let’s talk about the data surrounding the use of chimeric antigen receptor (CAR) T-cell therapy in earlier lines of treatment for relapsed/refractory multiple myeloma (R/R MM) (full abstracts at the end of guide):
- Ciltacabtagene autoleucel
- Idecabtagene vicleucel
- What are your thoughts about these data?
- Dr Abdallah to ask Dr Kort: What are the key factors that influence your institution’s decision to use CAR T-cell therapy in earlier lines of treatment for R/R MM?
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
